Pfizer said the decision was partly fueled by clinical studies showing a decrease in bococizumab’s efficacy, along with other unfavorable side effects, according to a company news release.
Tight market competition for this class of drugs may have also motivated the company’s decision, as Amgen’s drug Repatha and Sanofi-Regeneron’s Praluent are already on the market, Bloomberg Gadfly reports.
Pfizer estimates the cancellation of the bococizumab development program will negatively impact the company by about 4 cents per share. The drugmaker will record this loss as a research and development charge in the fourth quarter of 2016, according to the news release.
More articles on supply chain:
Valeant eyes potential $10B deal with Takedo to sell stomach drug business
Alabama pipeline explosion sends gas, diesel prices soaring: 6 things to know
Tyto Care’s digital stethoscope earns green light from FDA
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
